"R&D Trends: Renal Cell Cancer - Crowded RCC Market Remains Attractive to Drug Developers" Published
Renal cell cancer (RCC) continues to attract drug developers in spite of the crowded nature of the market. Currently approved targeted therapies have been unable to produce durable responses in RCC patients and only delay progression. As a consequence, effective treatment options capable of sustaining responses in RCC are still needed.
View full press release